Recent research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing significant effects in addressing excess mass and type non-insulin-dependent diabetes. Initial data suggest a distinct https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/